Excellent Primary Patency at 6 Months for the 4EVER Study Using the Pulsar Stent System With PROBIO Coating
The Society for Vascular Surgery® (SVS) and W. L. Gore & Associates (Gore) today announced an initiative that recognizes the contributions of female vascular surgeons and aims to advance the number of women entering the profession. Currently women account for only seven percent of board certified vascular surgeons, yet cardiovascular disease remains the nation’s number one killer among women. In a video released today, Eva Rzucidlo, MD, Chair of the SVS Women’s Leadership Committee and Vascular Surgeon, Dartmouth/Hitchcock Medical Center, discusses the need for more female vascular surgeons with the rising number of women diagnosed with vascular-related diseases.
NATICK, Mass., May 17, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System. The Epic Stent is designed to open blocked arteries in patients with iliac artery stenosis, a form of peripheral vascular disease associated with severe leg pain caused by insufficient blood flow.
Ten generic versions of the anti-clotting drug clopidogrel (Plavix) were approved en masse by the FDA on Thursday, coinciding with the expiration of a key patent on the drug. Two dosage forms for the generics were approved: 300 mg, produced by Gate, Mylan, and Teva; and 75 mg, manufactured by Apotex, Aurobindo, Mylan, Roxane, Sun Pharma, Teva, and Torrent.
Twelve-month results from the BIOSOLVE-I study with the DRug Eluting Absorbable Metal Scaffold (DREAMS) demonstrate safety and confirm vessel vasomotion. T he results from the BIOSOLVE-I study were presented at the European Course on Revascularization in Paris (EuroPCR) by Professor Michael Haude, Lukaskrankenhaus, Neuss, Germany.
LAS VEGAS -- Most patients with aorto-iliac disease should be treated endovascularly with stents rather than surgically, a researcher suggested after presenting results of the MOBILITY trial.
Medtronic has announced the availability of the Valiant Captivia Thoracic Stent Graft System for endovascular repair of aortic aneurysms in China, Japan and the United States.
Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease, according to results of the MOBILITY trial presented by Michael R Jaff , Boston, USA, on 10 May as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2012 Scientific Sessions in Las Vegas, USA.
Michael Gough, Leeds General Infirmary, Leeds, UK, presented long-term follow-up after endovenous laser ablation for great saphenous varicose veins at the 34th Charing Cross International Symposium in London, UK. The study reviewed a group of 63 patients (79 limbs) 6.5 years after above-knee laser treatment.
Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant® Captivia® Thoracic Stent Graft System in several countries, including China, Japan and the United States. "The expanded offering of the Valiant Captivia Stent Graft in these major global markets epitomizes our commitment to globalization," said Tony Semedo, general manager of the Endovascular Therapies business unit at Medtronic. "Now, more physicians across the globe than ever before will be able to offer their patients a minimally-invasive treatment option for life-threatening thoracic aortic aneurysms without the associated trauma of open surgery."
Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries
A first-in-man experience of the Enabler-P Balloon Catheter System (EndoCross) has shown positive outcomes in the treatment of peripheral artery disease. The results of the study were published in the current issue of the Journal of Endovascular Therapy.
Abbott (NYSE: ABT ) today announced that the U.S. Food and Drug Administration (FDA) approved the Absolute Pro® Vascular Self-Expanding Stent System for the treatment of iliac artery disease, a form of Peripheral Artery Disease (PAD) that affects the lower extremities. Over time, iliac artery disease can progress to where patients have reduced walking ability, experience chronic pain and suffer permanent disability. This approval is supported by the MOBILITY (Omnilink Elite® or Absolute Pro Stent Used in the Iliac Artery) study, which demonstrated that Absolute Pro is safe and effective, even in patients with complex disease.
Angioslide, a provider of embolic capture angioplasty solutions, announced on 2 May 2012 that it has received FDA 510(k) clearance for its new 3X100mm Proteus device for treating peripheral artery disease in below-the-knee vasculature. The new 3/100mm device accommodates 0.014” guidewires, which significantly broadens the potential use of Proteus technology.
Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, announces that it has received feedback from the U.S. Food and Drug Administration (“FDA”) as a result of its 100 day review. This review is part of the process for the pre-market approval (“PMA”) application for AorfixTM, the Company’s flexible stent graft for the endovascular repair of abdominal aortic aneurysms (“AAAs”). As previously announced the PMA filing was accepted for review in January 2012.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos